The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

Prostate cancer is the most common solid tumor in male patients. Roughly 70,000 U.S. adults each year are diagnosed with intermediate-risk disease confined to the prostate, for which radiation therapy ...

At the ICR, we are interested in how to make cancer treatments kinder and more practical for patients. With prostate cancer being the most common cancer in men in the UK and many other countries, and ...

TO RESPOND TO TREATMENT, AND PRESIDENT BIDEN’S DIAGNOSIS HAS A LOT OF PEOPLE ASKING QUESTIONS ABOUT PROSTATE CANCER. AND EARLIER TODAY ON KCRA THREE, WE ASKED OUR VIEWERS FOR SOME OF THEIR QUESTIONS ...